H.C. Wainwright lowered the firm’s price target on BioXcel Therapeutics (BTAI) to $5 from $6 and keeps a Buy rating on the shares. The firm cites the company’s recent and anticipated equity dilution for the target cut.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTAI: